The role of cytoreduction surgery in advanced ovarian cancer (review)
- Authors: Tandelov RK1,2, Sel'chuk VY.1,2, Morkhov KY.2, Nechushkina VM2,3, Kuznetsov VV2
-
Affiliations:
- A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
- N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
- N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 20, No 1 (2018)
- Pages: 5-10
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27150
- ID: 27150
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
R K Tandelov
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation; N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: romanyh@yandex.ru
аспирант каф. онкологии фак-та дополнительного профессионального образования, клиническая база - гинекологическое отд-ние НИИ КО 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
V Yu Sel'chuk
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation; N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: onkofpdo@gmail.com
д-р мед. наук, проф., зав. каф. онкологии фак-та дополнительного профессионального образования, глав. врач клинических институтов 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
K Yu Morkhov
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: oncogyn@ronc.ru
канд. мед. наук, ст. науч. сотр. гинекологического отд-ния НИИ КО 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
V M Nechushkina
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation; N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Email: oncogyn@ronc.ru
д-р мед. наук, проф. каф. онкологии, ст. науч. сотр. гинекологического отд-ния НИИ КО 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
V V Kuznetsov
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federationд-р мед. наук, проф., вед. науч. сотр. гинекологического отд-ния НИИ КО 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
References
- Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2013 г. М.: Издательская группа РОНЦ, 2015
- Baekelandt M. The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer 2003; 13 (Suppl. 2): 163-8. doi: 10.1111/j.1525-1438.2003.13354.x
- Meigs J.V. Tumors of the Female Pelvic Organs. New York, NY, Macmillan, 1934.
- Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42: 101-4.
- Pölcher M, Zivanovic O, Chi D.S. Cytoreductive surgery for advanced ovarian cancer. Womens Health (Lond) 2014; 10 (2): 179-90. doi: 10.2217/whe.14.4
- Omura G, Blessing J.A, Ehrlich C.E et al. A randomized trial of cyclophosphamide and doxorubicinum with or without cisplatin in advanced ovarian carcinoma. Cancer 1986; 57 (9): 1725-30. doi: 10.1002/1097-0142(19860501)57:9
- Omura G.A, Brady M.F, Homesley H.D et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9 (7): 1138-50. doi: 10.1200/JCO.1991.9.7.1138
- Chi D.S, Eisenhauer E.L, Lang J et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006; 103 (2): 559-64. doi: 10.1016/j.ygyno.2006.03.051
- Hoskins W.J, Bundy B.N, Thigpen J.T, Omura G.A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 1992; 47 (2): 159-66. doi: 10.1016/0090-8258(92)90100-W
- Eisenkop S.M, Spirtos N.M. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol 2001; 82 (3): 435-41. doi: 10.1006/gyno.2001.6313
- Bristow R.E, Tomacruz R.S, Armstrong D.K et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20 (5): 1248-59. doi: 10.1200/jco.2002.20.5.1248
- Bristow R.E, Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006; 103 (3): 1070-6. doi: 10.1016/j.ygyno.2006.06.025
- Чубенко В.А. Перспективные методы лечения злокачественных новообразований. Практическая онкология. 2007; 32 (4): 228-35.
- Skipper H.E. Adjuvant chemotherapy. Cancer 1978; 41 (3): 936-40. doi: 10.1002/1097-0142(197803)41:3
- Goldie J.H, Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63 (11-12): 1727-33.
- Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005; 10 (6): 370-81. doi: 10.1634/theoncologist.10-6-370
- Schorge J.O, McCann C, Del Carmen M.G. Surgical debulking of ovarian cancer: what difference does it make? Rev Obstet Gynecol 2010; 3 (3): 111-7. doi: 10.3909/riog0111
- Chi D.S, Eisenhauer E.L, Zivanovic O et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009; 114 (1): 26-31. doi: 10.1016/j.ygyno.2009.03.018
- Vergote I, Tropé C.G, Amant F et al; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363 (10): 943-53. doi: 10.1056/NEJMoa0908806
- Chi D.S, Musa F, Dao F et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012; 124 (1): 10-4. doi: 10.1016/j.ygyno.2011.08.014
- Морхов К.Ю., Нечушкина В.М., Кузнецов В.В. Хирургическое лечение рака яичников. Практическая онкология. 2014; 60 (4): 153-7.
- Kehoe S, Hook J, Nankivell M et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386 (9990): 249-57. doi: 10.1016/S0140-6736(14)62223-6